Analystreport

DiaMedica Therapeutics (NASDAQ:DMAC) had its "buy" rating reaffirmed by analysts at Lake Street Capital.

DiaMedica Therapeutics Inc.  (DMAC) 
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm Check Earnings Report